NORGESTIMATE AND ETHINYL ESTRADIOL kit

البلد: الولايات المتحدة

اللغة: الإنجليزية

المصدر: NLM (National Library of Medicine)

العنصر النشط:

NORGESTIMATE (UNII: C291HFX4DY) (NORGESTIMATE - UNII:C291HFX4DY), ETHINYL ESTRADIOL (UNII: 423D2T571U) (ETHINYL ESTRADIOL - UNII:423D2T571U)

متاح من:

Glenmark Pharmaceuticals Inc., USA

INN (الاسم الدولي):

NORGESTIMATE

تركيب:

NORGESTIMATE 0.18 mg

نوع الوصفة الطبية :

PRESCRIPTION DRUG

الخصائص العلاجية:

Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg and Norgestimate and Ethinyl Estradiol Tablets, 0.25 mg/0.035 mg are indicated for use by females of reproductive potential to prevent pregnancy [see Clinical Studies (14)]. Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg are indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Norgestimate and Ethinyl Estradiol Tablets, 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control [see Clinical Studies (14)]. Norgestimate and ethinyl estradiol tablets are contraindicated in females who are known to have or develop the following conditions: Risk Summary There is no use for contraception in pregnancy, therefore, norgestimate and ethinyl

ملخص المنتج:

Norgestimate and Ethinyl Estradiol Tablets, USP 0.25 mg/0.035 mg are available in blister packs containing 28 tablets, as follows: NDC 68462-309-29 1 carton containing 3 blister cards of 28 tablets Norgestimate and Ethinyl Estradiol Tablets, USP 0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg are available in blister packs containing 28 tablets, as follows: NDC 68462-565-29 1 carton containing 3 blister cards of 28 tablets

الوضع إذن:

Abbreviated New Drug Application

خصائص المنتج

NORGESTIMATE AND ETHINYL ESTRADIOL- NORGESTIMATE AND ETHINYL
ESTRADIOL
GLENMARK PHARMACEUTICALS INC., USA
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
NORGESTIMATE AND
ETHINYL ESTRADIOL TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS.
NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS, 0.25 MG/0.035 MG, FOR ORAL
USE
NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS, 0.18 MG/0.035 MG, 0.215
MG/0.035 MG,
0.25 MG/0.035 MG, FOR ORAL USE
INITIAL U.S. APPROVAL: 1989
WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
•
•
RECENT MAJOR CHANGES
Contraindications, Pregnancy (4) Removed 06/2023
INDICATIONS AND USAGE
Norgestimate and ethinyl estradiol tablets are combinations of
norgestimate, a progestin, and ethinyl
estradiol, an estrogen, indicated for use by females of reproductive
potential to prevent pregnancy. (1.1)
Norgestimate and ethinyl estradiol tablets 0.18 mg/0.035 mg, 0.215
mg/0.035 mg, 0.25 mg/0.035 mg are
indicated for the treatment of moderate acne vulgaris in females at
least 15 years of age, who have no
known contraindications to oral contraceptive therapy and have
achieved menarche.
Norgestimate and ethinyl estradiol tablets 0.18 mg/0.035 mg, 0.215
mg/0.035 mg, 0.25 mg/0.035 mg
should be used for the treatment of acne only if the patient desires
an oral contraceptive for birth control.
(1.2)
DOSAGE AND ADMINISTRATION
•
•
•
DOSAGE FORMS AND STRENGTHS
Norgestimate and Ethinyl Estradiol Tablets, USP 0.25 mg/0.035 mg,
consist of 28 round, flat faced beveled
edged, uncoated tablets in the following order (3):
•
•
Norgestimate and Ethinyl Estradiol Tablets, USP 0.18 mg/0.035 mg,
0.215 mg/0.035 mg, 0.25 mg/0.035
mg, consist of 28 round, flat faced beveled edged, uncoated tablets in
the following order (3):
•
•
•
•
CONTRAINDICATIONS
NORGESTIMATE AND ETHINYL ESTRADIOL TABLETS ARE CONTRAINDICATED IN
WOMEN